Keyphrases
Prostate Cancer
92%
Finland
53%
Lynch Syndrome
40%
Overall Survival
35%
Tumor
35%
Circulating Tumor DNA (ctDNA)
31%
Quality of Life
28%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
27%
Colorectal Cancer
27%
Prostate Cancer Risk
25%
Breast Cancer
25%
Confidence Interval
24%
Ovarian Cancer
23%
Cancer Cells
22%
Three-dimensional (3D)
20%
Chemotherapy
18%
Radiotherapy
18%
Prostate
17%
Glioblastoma
16%
Hazard Ratio
16%
Castration-resistant Prostate Cancer
15%
In Cancer
15%
Prognostic Factors
15%
Enzalutamide
15%
Health-related Quality of Life
15%
Adjuvant Therapy
15%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
15%
Metastatic Colorectal Cancer (mCRC)
15%
Androgen Deprivation Therapy
15%
Prostate Cancer Screening
14%
Acute Lymphoblastic Leukemia
14%
Pulmonary Metastasis
14%
ENGOT
14%
Androgen Receptor
14%
Palliative Care
14%
Programmed Death-ligand 1 (PD-L1)
14%
Population-based
13%
Cancer Evolution
13%
Progression-free Survival
13%
Prostate Cancer Progression
12%
Breast Cancer Patients
12%
Early Breast Cancer
12%
Mismatch Repair
12%
Methyl
11%
Metastasis
11%
Prostate Cancer Cells
11%
High Risk
11%
Advanced Prostate Cancer
11%
Microsatellite Stable Colorectal Cancer
10%
Nitrophenyl
10%
Indoline
10%
Renal Cell Carcinoma
10%
Recurrent Endometrial Cancer
10%
Dostarlimab
10%
Whole Genome
10%
Risk Variant
10%
Apoptosis
10%
Statins
10%
Tumor Cells
10%
Prostate Cancer Patients
10%
Pancreatic Ductal Adenocarcinoma
9%
Residual Disease
9%
Tumor Growth
9%
Solid Tumors
9%
Patient Survival
9%
Intermediate Risk
9%
Tyrosine Kinase Inhibitor
9%
University Hospital
9%
Gene Expression
9%
Magnetic Resonance Imaging
9%
High-grade Serous Ovarian Cancer (HGSOC)
9%
Retrospective Analysis
8%
Prostatectomy
8%
Leukemia
8%
PARP Inhibitor (PARPi)
8%
Treatment Strategy
8%
Single Center
8%
Patient-derived
8%
Older Adults
8%
T-cell Acute Lymphoblastic Leukemia (T-ALL)
8%
Functional Outcome
8%
Mitogen-activated Protein Kinase
8%
Epithelial Ovarian Cancer
8%
Cancer Risk
8%
5-year Survival
8%
Atorvastatin
8%
Signaling Pathway
8%
Abiraterone
8%
Prognostic Role
8%
Randomized Trial
8%
Colonoscopy Surveillance
8%
Targeted Therapy
8%
Computed Tomography
8%
Tumor Tissue
8%
Clinically Significant
8%
Placebo
7%
Immune Cell Score
7%
Visual Analog Scale
7%
Cancer Tissue
7%
Liquid Biopsy
7%
Medicine and Dentistry
Prostate Cancer
100%
Neoplasm
58%
Malignant Neoplasm
41%
Overall Survival
39%
Colorectal Carcinoma
35%
Breast Cancer
35%
Ovarian Cancer
32%
Quality of Life
24%
Prostatectomy
24%
Radiation Therapy
23%
Diseases
23%
Immunity
21%
Circulating Tumor DNA
19%
Symptomatic Treatment
19%
Acute Lymphoblastic Leukemia
18%
Hereditary Nonpolyposis Colorectal Cancer
18%
Cancer
17%
Prognostic Factor
16%
Castration Resistant Prostate Cancer
16%
Cancer Therapy
16%
Pediatrics
15%
Arm
15%
Cancer Cell
15%
Metastatic Carcinoma
14%
Metastatic Colorectal Cancer
14%
Progression Free Survival
14%
Lung Metastasis
14%
Clear Cell Renal Cell Carcinoma
14%
Hazard Ratio
14%
Immunotherapy
13%
Biological Marker
12%
Androgen Receptor
12%
DNA Mismatch Repair
12%
Cancer Mortality
12%
Primary Tumor
12%
Decision Making
11%
Magnetic Resonance Imaging
11%
Krukenberg Tumor
11%
Cancer Screening
11%
Oncology
11%
Immunocompetent Cell
11%
CD8 Antigen
10%
Gene Expression
10%
Cancer Growth
9%
Adjuvant Therapy
9%
Minimal Residual Disease
9%
Diagnosis
9%
Computer Assisted Tomography
9%
Leukemia
9%
Enzalutamide
8%
PARP Inhibitor
8%
Androgen
8%
Messenger RNA
8%
Bevacizumab
8%
Ganglioglioma
8%
Prostate Specific Antigen
7%
Cell Signaling Pathway
7%
Personalized Medicine
7%
Abiraterone
7%
Epithelial Cell
7%
Liquid Biopsy
7%
Wart Virus
7%
Carcinoembryonic Antigen
7%
Stomach Adenocarcinoma
7%
Visual Analog Scale
7%
Subgroup Analysis
7%
Clinical Management
7%
Dyspnea
7%
Programmed Death-Ligand 1
7%
Homologous Recombination
7%
Surgery
7%
Uterine Cancer
6%
Survival Rate
6%
Biopsy Technique
6%
CD3 Antigen
6%
Cohort Analysis
6%
Somatics
6%
Colonoscopy
6%
Urinary System
6%
Tumor Cell
6%
Cell Line
6%
In Vitro
6%
Disease Free Survival
6%
Statin
6%
Androgen Deprivation Therapy
6%
Kidney Metastasis
6%
Neoadjuvant Chemotherapy
6%
Adjuvant Chemotherapy
6%
Disease Exacerbation
6%
Continence
6%
Immune Response
5%
Prostate Adenocarcinoma
5%
Metastasectomy
5%
Recurrent Disease
5%
Retrospective Cohort Study
5%
Lipid Metabolism
5%
Germ Cell
5%
Interleukin 6
5%
Ovarian Cancer Cell Line
5%
Treatment Response
5%